Give every patient access to the most advanced cancer care
You’re committed to delivering the best patient care today, and tomorrow. Partnering with Personalis provides comprehensive genomic testing today, and ensures your testing capabilities will grow as the field of oncology evolves. We’re committed to empowering your treatment decisions through highly sensitive and ultra-comprehensive genomic profiling.
Test Background
Suitable for any patient with a solid tumor, the NeXT Dx test is a comprehensive genomics tumor profiling test based on augmented whole exome and transcriptome sequencing.
It works by analyzing the tumor’s genomic and molecular characteristics using clinical-grade, next-generation sequencing (NGS) technology to report small nucleotide variants (SNVs), small insertions and deletions (indels), copy number alterations (CNAs), fusions, MSI and exome-wide “true” TMB. Mutations in certain genes that may be germline in origin are reported as incidental findings. In addition, mutations in genes involved in homologous recombination repair (HRR) are highlighted when identified. A list of genes covered by the NeXT Dx test may be found here.
Industry Challenges
Many false positive variants
due to tumor-only approach
No germline variants
reported from tumor-only tests
Misses actionable mutations
Looks at DNA only
Difficult to add new biomarkers
TMB requires extrapolation
from panels
NeXT Dx™ Test Solution
Matched tumor-normal approach accurately identifies somatic variants
Germline variants are reported
as incidental findings
Fills in sequencing gaps left
by other testing solutions
Analyzes both DNA and RNA
Faster integration of new biomarkers
Gold-standard exome wide
TMB assessment
1. Solomon et al., Modern Pathology, 2020
Process
Additional Resources
Contact Information
Client Services
+1 (855) 373-7978 or [email protected]
6:00 a.m. – 5:00 p.m. PST, weekdays.
Patient Billing Services
+1 (855) 373-7974 or [email protected]
6:30 a.m. – 4:00 p.m. PST, weekdays.